Clinical Trial Update: IRESSA in Combination With Cisplatin & Radiotherapy in Patients With Advanced Head & Neck Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating gefitinib (IRESSA) in combination with cisplatin and radiotherapy for advanced head and neck cancer; the study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer

Drugs mentioned

• CISPLATIN (cisplatin)
• Iressa (gefitinib)

Snippet

Sponsor: AstraZeneca | Conditions: Cancer of Head and Neck | Phase 2 | Status: COMPLETED